Diagnosis of renal tumors by in vivo proton magnetic resonance spectroscopy

World Journal of Urology

Volumn 33, Issue 1, 2015, Pages 17-23

  Sevcenco, Sabina ^a   Krssak, Martin ^a   Javor, Domagoj ^a   Ponhold, Lothar ^a   Kuehhas, Franklin E ^a   Fajkovic, Harun ^a   Haitel, Andrea ^a   Shariat, Sharokh F ^a   Baltzer, Pascal A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Diagnosis; Magnetic resonance imaging; MR spectroscopy; Renal cell carcinoma; Renal masses; Sensitivity and specificity

Indexed keywords

BIOLOGICAL MARKER; CHOLINE;

ADULT; AGED; CARCINOMA, RENAL CELL; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; KIDNEY NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CARCINOMA, RENAL CELL; CHOLINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTON MAGNETIC RESONANCE SPECTROSCOPY; ROC CURVE;

EID: 84895124360     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1272-y     Document Type: Article

References (23)

1. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98:1331–1334
2. Brookman-May S, Langenhuijsen JF, Volpe A et al (2013) Management of localized and locally advanced renal tumors. A contemporary review of current treatment options. Minerva Med 104:237–259
3. Kovacs G, Akhtar M, Beckwith BJ et al (1997) The Heidelberg classification of renal cell tumors. J Pathol 183:131–133
4. Veltri A, Garetto I, Tosetti I et al (2011) Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol 21:393–401
5. Leveridge MJ, Finelli A, Kachura JR et al (2011) Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol 60:578–584
6. Macari M, Bosniak MA (1999) Delayed CT to evaluate renal masses incidentally discovered at contrast-enhanced CT: demonstration of vascularity with deenhancement. Radiology 213:674–680
7. Morgan B, Thomas AL, Drevs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol Off J Am Soc Clin Oncol 21:3955–3964
8. Sun MR, Ngo L, Genega EM et al (2009) Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes—correlation with pathologic findings. Radiology 250:793–802
9. Kim JH, Bae JH, Lee KW, Kim ME, Park SJ, Park JY (2012) Predicting the histology of small renal masses using preoperative dynamic contrast-enhanced magnetic resonance imaging. Urology 80:872–876
10. Vargas HA, Chaim J, Lefkowitz RA et al (2012) Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes. Radiology 264:779–788
11. Wang H, Cheng L, Zhang X et al (2010) Renal cell carcinoma: diffusion-weighted MR imaging for subtype differentiation at 3.0 T. Radiology 257:135–143
12. Taouli B, Thakur RK, Mannelli L et al (2009) Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology 251:398–407
13. Yuen JS, Thng CH, Tan PH et al (2004) Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy. J Urol 171:1482–1486
14. Haddadin IS, McIntosh A, Meisamy S et al (2009) Metabolite quantification and high-field MRS in breast cancer. NMR Biomed 22:65–76
15. Katz-Brull R, Rofsky NM, Morrin MM et al (2005) Decreases in free cholesterol and fatty acid unsaturation in renal cell carcinoma demonstrated by breath-hold magnetic resonance spectroscopy. Am J Physiol Renal Physiol 288:F637–F641
16. Sullentrop F, Hahn J, Moka D (2012) In vitro and in vivo (1)H-MR spectroscopic examination of the renal cell carcinoma. Int J Biomed Sci (IJBS) 8:94–108
17. Kim DY, Kim KB, Kim OD, Kim JK (1998) Localized in vivo proton spectroscopy of renal cell carcinoma in human kidney. J Korean Med Sci 13:49–53
18. Righi V, Mucci A, Schenetti L et al (2007) Ex vivo HR-MAS magnetic resonance spectroscopy of normal and malignant human renal tissues. Anticancer Res 27:3195–3204
19. Hammer S, de Vries AP, de Heer P et al (2013) Metabolic imaging of human kidney triglyceride content: reproducibility of proton magnetic resonance spectroscopy. PLoS One 8:e62209
20. Naressi A, Couturier C, Devos JM et al (2001) Java-based graphical user interface for the MRUI quantitation package. Magma 12:141–152
21. Baltzer PA, Dietzel M (2013) Breast lesions: diagnosis by using proton MR spectroscopy at 1.5 and 3.0 T—systematic review and meta-analysis. Radiology 267:735–746
22. Mancini V, Battaglia M, Ditonno P et al (2008) Current insights in renal cell cancer pathology. Urol Oncol 26:225–238
23. Jorns J, Thiel DD, Lohse CM et al (2012) Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma. BJU Int 110(7):956–960